A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
出版年份 2021 全文链接
标题
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
作者
关键词
-
出版物
Cancers
Volume 13, Issue 16, Pages 3994
出版商
MDPI AG
发表日期
2021-08-09
DOI
10.3390/cancers13163994
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Potent Cytolytic Activity and Specific IL15 Delivery in a 2nd Generation Trispecific Killer Engager
- (2020) Martin Felices et al. Cancer Immunology Research
- NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
- (2020) Daniel A. Vallera et al. Cancers
- IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion
- (2019) Kevin C Conlon et al. CLINICAL CANCER RESEARCH
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands
- (2018) M. Timmermans et al. EUROPEAN JOURNAL OF CANCER
- The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies
- (2018) Hui Luo et al. PLoS One
- Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
- (2017) Gulden Menderes et al. GYNECOLOGIC ONCOLOGY
- IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer
- (2017) M. Felices et al. GYNECOLOGIC ONCOLOGY
- Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer
- (2017) Hope S. Rugo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
- (2017) Ander Urruticoechea et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer
- (2014) Yunlang Cai et al. MEDICAL ONCOLOGY
- Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition
- (2013) Benoît Thibault et al. CANCER AND METASTASIS REVIEWS
- HER2-positive gastric cancer
- (2013) Narikazu Boku Gastric Cancer
- Densely Granulated Murine NK Cells Eradicate Large Solid Tumors
- (2012) R. B. Liu et al. CANCER RESEARCH
- Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels
- (2012) Evripidis Lanitis et al. PLoS One
- Interleukin-15 biology and its therapeutic implications in cancer
- (2011) Jason C. Steel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Ovarian cancer creates a suppressive microenvironment to escape immune elimination
- (2010) Refika Yigit et al. GYNECOLOGIC ONCOLOGY
- Targeting signaling pathways in ovarian cancer
- (2008) J Reibenwein et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
- (2008) Cécile Vincke et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More